Insulin sensitizers and atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Metabolic Syndrome

Background:

• Insulin resistance is a key factor in diabetes mellitus development.
• Insulin resistance contributes to atherosclerosis through associated metabolic abnormalities.
• The cluster of insulin resistance-related issues is known as multiple risk factor syndrome.

Purpose of the Study:

• To review previous studies on the anti-atherogenic effects of insulin sensitizers.
• To explore various strategies employed by insulin sensitizers to combat atherosclerosis.
• To provide evidence supporting the potential use of insulin sensitizers as anti-atherogenic agents.

Main Methods:

• Literature review of existing studies on insulin sensitizers and atherosclerosis.
• Analysis of different therapeutic strategies involving insulin sensitizers.
• Synthesis of data on the anti-atherogenic mechanisms of these drugs.

Main Results:

• Insulin resistance is linked to glucose intolerance, hyperlipidemia, and hypertension, collectively increasing atherosclerosis risk.
• Several insulin sensitizing drugs are now used for diabetes treatment.
• Data on the direct, large-scale clinical efficacy of insulin sensitizers against atherosclerosis is limited due to recent drug approval.

Conclusions:

• Insulin sensitizers demonstrate potential anti-atherogenic properties through various mechanisms.
• Further research and large-scale clinical trials are warranted to confirm the role of insulin sensitizers in preventing atherosclerosis.
• Insulin sensitizers are expected to be valuable therapeutic options for managing atherosclerosis in at-risk populations.